#USA #College Park #COPD #Altesa BioSciences #Vapendavir

Altesa BioSciences to Present at ERS Congress 2026

In a significant development for the treatment of chronic lung diseases, Altesa BioSciences has announced that new clinical data on vapendavir will be presented at the upcoming European Respiratory Society (ERS) International Congress 2026, set to take place from September 5 to 9 in Barcelona, Spain. This investigational drug is a potential breakthrough in managing COVID-associated acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).

The Role of Vapendavir

Vapendavir is an oral rhinovirus capsid inhibitor, which means it works by targeting and disrupting the virus's ability to replicate. Rhinovirus is notorious for causing approximately 50% of acute exacerbations in COPD patients. The upcoming abstract titled "Inflammatory Biomarkers Are Reduced by Vapendavir Treatment in Rhinovirus-Challenged COPD Patients" will be presented by Dr. Sebastian Johnston, a leading respiratory researcher from VirTus Respiratory Research in London.

This oral presentation aims to summarize findings from a double-blind, placebo-controlled study that evaluated the effects of vapendavir on immune responses in COPD patients who were challenged with rhinovirus. Details surrounding additional findings will remain under embargo until the presentation on September 9, which will focus on respiratory infections and the host's response, complications, and interventions.

Implications for COPD

Acute exacerbations of COPD are a significant concern, having serious impacts on patient morbidity and mortality. These exacerbations are closely linked to accelerated lung function decline and a significantly reduced quality of life. With rhinovirus being a primary culprit, the ability of vapendavir to reduce inflammation could shift the treatment paradigm for COPD patients.

Dr. Katharine Knobil, Chief Medical Officer of Altesa BioSciences, expressed enthusiasm for the upcoming presentation. She stated, “Being selected for an oral presentation at ERS underscores the strength and momentum behind our clinical program. Vapendavir's potential to disrupt the cycle of inflammation and exacerbation represents a paradigm shift not only for COPD patients but for all at-risk individuals.” This sentiment suggests that vapendavir may not only serve COPD patients but could also have broader implications for people vulnerable to respiratory viral infections.

Ongoing Clinical Trials

In addition to this pivotal presentation, Altesa BioSciences is actively progressing with its clinical trials. The Phase 2b CARDINAL trial has recently enrolled its first patient. The objective of this trial is to further investigate how vapendavir may alleviate both upper and lower airway symptoms, reduce the illness duration, and improve lung function in the small airways when compared with a placebo.

Future of Respiratory Treatments

The innovative approach represented by vapendavir could fill critical gaps in the current treatment landscape, offering new hope to millions of people suffering from COPD. With no existing approved treatments or vaccines for rhinovirus infections, the anticipation surrounding vapendavir's potential approval is palpable.

Altesa BioSciences is firmly dedicated to tackling the unmet medical needs associated with viral respiratory diseases, making the research and results shared at the ERS Congress crucial not just for their business but for public health as a whole. As the healthcare community eagerly awaits the results, the success of vapendavir could signal a new era in the management of respiratory complications linked to viral infections.